Novartis Investigative Site

Amiens Cedex1 80054

0 studies enrolling now · 2 studies all time

What they study most

Diffuse Large B-cell Lymphoma, Graft-versus-host Disease (GVHD)

Studies at this site

• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed